UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Buys 18,782 Shares of Cencora, Inc. (NYSE:COR)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in Cencora, Inc. (NYSE:COR) by 1.2% during the third quarter, Holdings Channel.com reports. The firm owned 1,552,213 shares of the company’s stock after purchasing an additional 18,782 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Cencora were worth $349,372,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently bought and sold shares of COR. Kennedy Capital Management LLC bought a new position in Cencora in the 1st quarter worth $705,000. Jacobs Levy Equity Management Inc. bought a new stake in Cencora during the first quarter valued at about $2,194,000. B. Riley Wealth Advisors Inc. bought a new stake in Cencora during the first quarter valued at about $411,000. LRI Investments LLC bought a new stake in Cencora during the first quarter valued at about $31,000. Finally, Cetera Investment Advisers bought a new stake in Cencora during the first quarter valued at about $16,625,000. 97.52% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

COR has been the topic of a number of recent analyst reports. Leerink Partners decreased their price target on Cencora from $277.00 to $275.00 and set an “outperform” rating on the stock in a report on Monday, October 7th. Barclays boosted their target price on Cencora from $263.00 to $290.00 and gave the stock an “overweight” rating in a research report on Thursday, November 7th. JPMorgan Chase & Co. boosted their target price on Cencora from $280.00 to $287.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 21st. Wells Fargo & Company boosted their target price on Cencora from $236.00 to $249.00 and gave the stock an “equal weight” rating in a research report on Thursday, August 1st. Finally, Evercore ISI boosted their target price on Cencora from $250.00 to $285.00 and gave the stock an “outperform” rating in a research report on Thursday, November 7th. Three research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat.com, Cencora presently has a consensus rating of “Moderate Buy” and a consensus price target of $271.20.

Insider Activity

In other news, Chairman Steven H. Collis sold 50,000 shares of the company’s stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $243.97, for a total transaction of $12,198,500.00. Following the transaction, the chairman now owns 326,557 shares of the company’s stock, valued at approximately $79,670,111.29. This represents a 13.28 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Over the last 90 days, insiders have sold 93,018 shares of company stock valued at $22,478,942. 15.80% of the stock is currently owned by insiders.

Cencora Trading Up 0.5 %

Shares of COR stock opened at $249.69 on Friday. The company has a market cap of $49.20 billion, a PE ratio of 33.25, a price-to-earnings-growth ratio of 1.63 and a beta of 0.44. The stock’s 50 day simple moving average is $234.44 and its two-hundred day simple moving average is $232.26. Cencora, Inc. has a 1 year low of $195.83 and a 1 year high of $251.56. The company has a debt-to-equity ratio of 4.84, a current ratio of 0.88 and a quick ratio of 0.53.

Cencora Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, November 29th. Stockholders of record on Friday, November 15th will be paid a dividend of $0.55 per share. This is a boost from Cencora’s previous quarterly dividend of $0.51. The ex-dividend date of this dividend is Friday, November 15th. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.88%. Cencora’s dividend payout ratio is currently 29.29%.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.